|
|
|
|
| LEADER |
01000cam a22002652 4500 |
| 001 |
748768599 |
| 003 |
DE-627 |
| 005 |
20230911152919.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
130604s2013 ne |||||o 00| ||eng c |
| 020 |
|
|
|a 9780124071803
|9 978-0-12-407180-3
|
| 035 |
|
|
|a (DE-627)748768599
|
| 035 |
|
|
|a (DE-599)GBV748768599
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XA-NL
|
| 050 |
|
0 |
|a HD9665.5
|
| 060 |
|
0 |
|a 2013 G-572
|
| 060 |
|
0 |
|a QV 745
|
| 084 |
|
|
|a ZD 27260
|q SEPA
|2 rvk
|0 (DE-625)rvk/155593:
|
| 084 |
|
|
|a 44.40
|2 bkl
|
| 084 |
|
|
|a 44.05
|2 bkl
|
| 100 |
1 |
|
|a Bartfai, Tamas
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The future of drug discovery
|b who decides which diseases to treat?
|c Tamas Bartfai; Graham V. Lees
|
| 264 |
|
1 |
|a Burlington
|b Elsevier Science
|c 2013
|
| 300 |
|
|
|a Online-Ressource (XXX, 346 S.)
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Description based upon print version of record
|
| 505 |
8 |
0 |
|a Front Cover; Expert Reviews for The Future of Drug Discovery: Who Decides Which Diseases to Treat?; Dedication; The Future of Drug Discovery: Who Decides which diseases to Treat?; Copyright; Content; Preface; Foreword by Graeme Bilbe PhD; Foreword by James H Eberwine PhD; Foreword by Eduard Enrico Holdener MD; Chapter 00: Introduction; Chapter 01 - Why there will be new drugs despite the ongoing "crisis" of drug development in Big Pharma; Pharmaceutical industry in crisis & consolidation; Why is there a strong belief that new future medicines will come?
|
| 505 |
8 |
0 |
|a Safe drugs in new indications: one does not always need new drugs for new therapiesPreventive drugs: large, long, expensive, convincing trials; Age as a risk factor & keeping costs in check; Newly orphaned diseases: more government needed; Chapter 02 - The need for medicines grows; Small molecules & biologicals; The aging population; Rare or "orphan" diseases; Drug development: adding biologicals; Treatment of MS; Treatment of RA; Recombinant proteins as treatments; Future recombinant proteins as treatments; Pharma, governments, & nongovernmental organizations
|
| 505 |
8 |
0 |
|a Chapter 03 - Medicines are becoming better: some of the breakthrough medicines of the past decadesSignificant progress since WW II; The great beginning & the feared end of extremely profitable drug discovery; Drug discovery recovery, phase 1; Drug discovery arrested?; Meta-analysis matters: new twist on old information; New uses for safe drugs; Off-label use in other indications; Life cycle extension by repositioning; Inter- & intra-company competition to replace approved drugs in financially attractive indications; Pricing policies
|
| 505 |
8 |
0 |
|a Greater emphasis on long-term drug safety & benefit-risk ratioMoving the goalposts; Gains of & from EBM; Numbers of annually approved drugs; Chapter 04 - Which diseases do we want to treat?; How many diseases are there?; How pharma companies have selected which diseases to treat; The funding & direction of biomedical research; The scientific basis of disease treatment; New avenues of research & the emergence of biosimilars; Generic drug makers; Biosimilars; "Firsts in class," "me-toos," & "best in class": marketers' dreams; Rescuing successful phase 2 candidates from oblivion
|
| 505 |
8 |
0 |
|a Una¢¢ounted ue of afe drugNGOs; Creating indications in the clinic or at the FDA?; Off-label use definitely enables approved drugs to treat additional diseases, but is it a desired tactic?; How can society affect the selection of indications by Big Pharma & by biotech?; Chapter 05 - Therapeutic areas: strategically important diseases of the future; Diverging views of society & industry; The human & economic cost of major diseases; AD: the most loomingly threatening disease; Early diagnostic imperatives; Translational research; Obesity & type 2 diabetes; Surgical versus drug interventions
|
| 505 |
8 |
0 |
|a Neuropathic pain
|
| 520 |
|
|
|a This book provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs
|
| 520 |
|
|
|a The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By ana
|
| 530 |
|
|
|a Electronic reproduction; Available via World Wide Web
|
| 533 |
|
|
|a Online-Ausg.
|d 2013
|n Electronic reproduction; Available via World Wide Web
|7 |2013||||||||||
|
| 650 |
|
0 |
|a Pharamacology, Experimental
|
| 650 |
|
0 |
|a Drug development
|
| 650 |
|
0 |
|a Drugs
|x Design
|
| 650 |
|
0 |
|a Pharmacology, Experimental
|
| 650 |
|
2 |
|a Drug Design
|
| 650 |
|
2 |
|a Drug Discovery
|
| 655 |
|
0 |
|a Electronic books
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)4003120-2
|0 (DE-627)106390600
|0 (DE-576)208850341
|a Arzneimittelforschung
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)4143176-5
|0 (DE-627)104408812
|0 (DE-576)209724234
|a Arzneimittelentwicklung
|2 gnd
|
| 689 |
0 |
2 |
|D s
|0 (DE-588)4113743-7
|0 (DE-627)105827177
|0 (DE-576)209478977
|a Gesundheitspolitik
|2 gnd
|
| 689 |
0 |
3 |
|D s
|0 (DE-588)4418449-9
|0 (DE-627)213732858
|0 (DE-576)212239848
|a Arzneimittelwirtschaft
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Lees, Graham V.
|e verfasserin
|4 aut
|
| 776 |
1 |
|
|z 9781299619203
|c (MyiLibrary)
|
| 776 |
1 |
|
|z 9780124095199
|c : 49.42 (UA)
|
| 776 |
0 |
8 |
|i Print version
|a The Future of Drug Discovery
|d Who Decides Which Diseases to Treat?
|
| 776 |
0 |
8 |
|i Druckausg.
|a Bartfai, Tamas
|t The future of drug discovery
|d Amsterdam : Academic Press, 2013
|h XXX, 346 S.
|w (DE-627)755455568
|w (DE-576)394284151
|z 9780124071803
|
| 856 |
4 |
0 |
|u http://www.sciencedirect.com/science/book/9780124071803
|x Verlag
|y ScienceDirect
|3 Volltext
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bowker/toc/9780124071803.pdf
|m V:DE-601
|m X:Bowker
|q pdf/application
|v 2016-12-13
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a ZDB-33-EBS
|
| 912 |
|
|
|a ZDB-33-ESD
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a ISIL_DE-18
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_22_i06404
|
| 912 |
|
|
|a GBV_ILN_105
|
| 912 |
|
|
|a ISIL_DE-841
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a ISIL_DE-715
|
| 936 |
r |
v |
|a ZD 27260
|b Arzneimittelkunde
|k Agrar- und Forstwissenschaft, Gartenbau, Ernährungs- und Haushaltswissenschaft
|k Nutztierwissenschaften
|k Tierheilkunde
|k Pathologie und Therapie
|k Arzneimittelkunde
|0 (DE-627)1272054470
|0 (DE-625)rvk/155593:
|0 (DE-576)202054470
|
| 936 |
b |
k |
|a 44.40
|j Pharmazie
|j Pharmazeutika
|q SEPA
|0 (DE-627)106423304
|
| 936 |
b |
k |
|a 44.05
|j Gesundheitsökonomie
|q SEPA
|0 (DE-627)106409611
|
| 936 |
s |
n |
|a MED
|2 bisac
|
| 936 |
s |
n |
|a MED
|2 bisac
|
| 936 |
s |
n |
|a MED
|2 bisac
|
| 936 |
s |
n |
|a MED
|2 bisac
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 338.4761519
|
| 980 |
|
|
|2 22
|1 01
|x 0018
|b 1480929026
|h h64 NEWL 06-2014
|k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y zi06404
|z 01-07-14
|
| 980 |
|
|
|2 105
|1 01
|x 0841
|b 1546479252
|c 05
|f --%%--
|d KaufEBook202103
|e --%%--
|j --%%--
|h OLR-ELV-TEST-2015
|k Testzugang ZHB Lübeck 2015. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y z
|z 16-06-15
|
| 980 |
|
|
|2 120
|1 02
|x 0715
|b 1644131595
|k Campusweiter Zugriff (Universität Oldenburg). - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y z
|z 02-11-16
|
| 980 |
|
|
|2 120
|1 05
|x 0715
|b 1753345669
|c 00
|f --%%--
|d --%%--
|e g
|j --%%--
|h alma
|k ww
|y z
|z 22-02-18
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Volltextzugang Campus
|r http://www.sciencedirect.com/science/book/9780124071803
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus
|r http://emedien.sub.uni-hamburg.de/han/ScienceDirectBookseriesUKE/www.sciencedirect.com/science/book/9780124071803
|
| 981 |
|
|
|2 105
|1 01
|x 0841
|r http://www.sciencedirect.com/science/book/9780124071803
|
| 981 |
|
|
|2 120
|1 02
|x 0715
|r http://www.sciencedirect.com/science/book/9780124071803
|
| 981 |
|
|
|2 120
|1 05
|x 0715
|r http://49gbv-uob-primo.hosted.exlibrisgroup.com/openurl/49GBV_UOB/UOB_services_page?u.ignore_date_coverage=true&rft.mms_id=991014217909703501
|
| 983 |
|
|
|2 120
|1 00
|x DE-715
|8 99
|a ww
|
| 985 |
|
|
|2 22
|1 01
|x 0018
|a h64 ebook
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 NEWL 06-2014
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 Elsevier
|
| 995 |
|
|
|2 105
|1 01
|x 0841
|a OLR-ELV-TEST-2015
|
| 995 |
|
|
|2 120
|1 05
|x 0715
|a alma
|
